tada, Resverlogix has engaged Rothschild & Co. as its financial advisor to evaluate a potential U.S. listing. As they say better later than never. Rather than follow the same path as Resverlogix management should take the bull by the horn and IPO Zenith Epigenetics Ltd., (not ZCC) on Nasdaq with their lead drug ZEN-3694 where the big money is. If ZEN-3694 has teeth it will move a lot quicker on Nasdaq right out of the starting gate, on a long-term basis. Let Rothschild & Co. show them the way. The sooner the better.

As I said, taking a page from Denali may not be so bad if they can get it. (IMO)

Koo